GET DAILY SIGNALSInMed Pharmaceuticals (INM): Pipeline Focus on CB1 and CB2 Receptors Alongside BayMedica Operations
Key Takeaways
- INM is the Nasdaq ticker for InMed Pharmaceuticals Inc., a clinical-stage biopharmaceutical company headquartered in Vancouver, Canada.
- The company develops proprietary small-molecule drug candidates targeting the body's cannabinoid receptors (CB1 and CB2), with programs focused on Alzheimer's disease, dry age-related macular degeneration, and certain skin conditions.
- Through its BayMedica subsidiary, InMed also manufactures and sells bulk rare, non-intoxicating cannabinoids as ingredients for the health-and-wellness sector.
- As a development-stage business, InMed has historically reported limited revenue and recurring operating losses, a common financial profile for early-stage drug developers.
- In late 2026, InMed completed a merger with the privately held Mentari Therapeutics and announced plans to trade under the new name Mentari Therapeutics, Inc.
Company Background
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel, small-molecule drug candidates that act on the body's endocannabinoid system. Investors follow INM because the company occupies a specialized niche at the intersection of pharmaceutical research and rare-cannabinoid science, pursuing treatments for conditions with significant unmet medical need. Its company overview centers on a pipeline of proprietary compounds aimed at Alzheimer's disease, age-related macular degeneration, and dermatological indications, alongside a commercial ingredients business operated through its wholly owned subsidiary, BayMedica.
Operational Details
InMed Pharmaceuticals was incorporated in the Province of British Columbia, Canada, in 1981 and is based in Vancouver. The company was formerly known as Cannabis Technologies Inc. before adopting the InMed Pharmaceuticals name in 2014. Its shares trade on the Nasdaq Capital Market under the symbol INM.
InMed's business model combines pharmaceutical research and development with a business-to-business ingredients operation. The company's drug-discovery efforts focus on "preferential signaling ligands" of the CB1 and CB2 receptors, which are part of the endocannabinoid system found throughout the human body and involved in numerous homeostatic functions, including neuroinflammation and immune response. By targeting these receptors, InMed aims to develop treatments that modulate multiple biological pathways linked to disease.
The company's clinical pipeline includes three principal programs:
- INM-901, a small-molecule drug candidate being developed as a potential treatment for Alzheimer's disease, with mechanisms acting on both CB1 and CB2 receptors.
- INM-089, an ocular research candidate exploring potential neuroprotective effects in dry age-related macular degeneration (dry AMD), a progressive eye condition.
- INM-755, a cannabinol cream that has completed a Phase 2 clinical trial evaluating safety and efficacy in treating symptoms related to epidermolysis bullosa, a group of rare skin disorders.
Complementing its pharmaceutical work, BayMedica specializes in manufacturing and selling bulk rare, non-intoxicating cannabinoids as raw ingredients for the health-and-wellness market. InMed has developed several proprietary manufacturing approaches, including chemical synthesis, biosynthesis, and a method called IntegraSyn, which the company uses to produce high-purity ingredients and drug candidates cost-effectively. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Why This Stock Draws Attention
InMed attracts attention primarily because of its exposure to areas of high unmet medical need. Alzheimer's disease and dry AMD affect large and growing patient populations, and any meaningful clinical success could significantly alter the company's financial profile. Its focus on the CB1/CB2 receptor pathway also gives it a differentiated scientific position within the broader cannabinoid and neuroscience research landscape.
The BayMedica segment provides a secondary growth driver, offering a commercial revenue channel that is somewhat separate from the long timelines typical of drug development. For investors comfortable with early-stage biotech risk, InMed's pipeline, intellectual property, and manufacturing expertise represent the key elements of its long-term market position. From what I see, this dual approach sets it apart from many pure-play developers.
Key Risks to Consider
Investing in INM involves substantial risks typical of clinical-stage pharmaceutical companies. InMed has historically reported significant operating losses and an accumulated deficit, and it may require additional capital to fund its research programs. There is no guarantee that its drug candidates will succeed in clinical trials or receive regulatory approval.
Other considerations include intense competition from larger, better-capitalized pharmaceutical firms, dependence on scientific and clinical milestones, and the regulatory and commercial uncertainty surrounding cannabinoid-based products. The company's relatively small size and limited revenue also make it sensitive to financing conditions and changes in investor sentiment toward the biotechnology sector.
Conclusion
InMed Pharmaceuticals (INM) is a small, clinical-stage biopharmaceutical company positioned at the intersection of neuroscience research and rare-cannabinoid science. Its pipeline of CB1/CB2-targeting drug candidates and its BayMedica ingredients business give it a distinctive, if speculative, profile. While the company's recent merger with Mentari Therapeutics has introduced a new chapter in its corporate story, its long-term relevance will ultimately depend on clinical progress, financing, and its ability to convert promising research into commercially viable treatments.
AI-Powered Research Tools
As part of my ongoing research into early-stage biotech names like this one, I regularly use Tickeron’s AI Screener to screen for technical indicators, fundamentals, and industry patterns. It helps surface ideas that align with specific strategies without replacing deeper fundamental analysis. This platform has become a practical step in building and refining watchlists for names operating in specialized sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INM's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for INM moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 instances where the indicator moved out of the overbought zone. In 14 of the 14 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 30 cases where INM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
INM broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on INM as a result. In 79 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
INM moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INM crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where INM advanced for three days, in 150 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. INM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: INM's P/B Ratio (79.518) is slightly higher than the industry average of (7.271). P/E Ratio (-4.987) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.891) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement